Page last updated: 2024-11-09

cinnamoylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cinnamoylglycine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-cinnamoylglycine : An N-acylglycine in which the acyl group is specified as (2E)-3-phenylprop-2-enoyl (cinnamoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID709625
CHEMBL ID456606
CHEBI ID68616
SCHEMBL ID9309519
SCHEMBL ID1558162
MeSH IDM0238992

Synonyms (42)

Synonym
cinnamoylglycine
IDI1_017289
n-cinnamylglycine
16534-24-0
C551E21D-9A7D-40AE-83A5-11794CD47554
glycine, n-cinnamoyl-
ECED132A-EF7F-427F-A985-F27822E561C9
glycine, n-cinnamoyl-, e-
HMS1447M06
AKOS000203043
2-[[(e)-3-phenylprop-2-enoyl]amino]acetic acid
chebi:68616 ,
CHEMBL456606
62430-40-4
glycine, n-(1-oxo-3-phenyl-2-propenyl)-
2-(3-phenylprop-2-enamido)acetic acid
EN300-10753
glycine,n-(1-oxo-3-phenyl-2-propen-1-yl)-
n-[(2e)-3-phenylprop-2-enoyl]glycine
n-(1-oxo-3-phenyl-2-propenyl)-glycine
n-cinnamoylglycine
AB00082962-01
STL363041
CS-M1704
2-cinnamamidoacetic acid
SCHEMBL9309519
SCHEMBL1558162
2-[(2e)-3-phenylprop-2-enamido]acetic acid
n-cinnamoylglycine, analytical reference material
CCG-245338
n-cinnamoyl-glycine
2-(3-phenylacrylamido)acetic acid
n-(1-oxo-3-phenyl-2-propen-1-yl)-glycine
Q27137048
HY-77641
CS-13471
glycine, n-(1-oxo-3-phenyl-2-propen-1-yl)-
EN300-1448663
2-cinnamamidoaceticacid
mfcd00136326
Z56883153
cinnamoyl glycine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
N-acylglycineAn N-acyl-amino acid in which amino acid specified is glycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID388273Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID388272Activity of rat recombinant peptidylglycine alpha-amidating monooxygenase assessed as stimulation of oxygen consumption2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID388274Ratio of Vm(app) to Km(app) for rat recombinant peptidylglycine alpha-amidating monooxygenase relative to hippuric acid2008Bioorganic & medicinal chemistry, Dec-01, Volume: 16, Issue:23
Substituted hippurates and hippurate analogs as substrates and inhibitors of peptidylglycine alpha-hydroxylating monooxygenase (PHM).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.61 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]